Treatment options in first-line metastatic kidney cancer
Over the past 10 years or so, the use of [...]
Real world treatment of advanced kidney cancer
Nearly 30% of new kidney cancer cases are diagnosed at [...]
Nivolumab compared to cabozantinib as a second- or third-line treatment
This study looked at real world data from people with [...]
EIKCS 2022: Real world use of immunotherapy and survival in metastatic kidney cancer
At the 2022 European International Kidney Cancer Symposium (EIKCS) in [...]
Real world incidence of immune-related side effects to ipilimumab/nivolumab in kidney cancer patients
A recent study published in Journal of Clinical Medicine this [...]
Active surveillance of metastatic kidney cancer
Active surveillance involves closely watching a patient's condition but not [...]
Real-world clinical outcomes with first-line sunitinib for metastatic kidney cancer
A paper published in The Oncologist last month analysed real-world [...]
Real world use of pazopanib after immunotherapy for advanced kidney cancer
A study published in Clinical Genitourinary Cancer last month describes [...]
Developments in data for rare and less common cancers
Cancer52 and the National Cancer Registration and Analysis Service (NCRAS) [...]
Data-driven approach to personalised care
One of the greatest strengths of the NHS is its [...]
